Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders
Orly R. Klein(Sidney Kimmel Comprehensive Cancer Center), Heather J. Symons(Johns Hopkins University), David M. Loeb(Albert Einstein College of Medicine), Jeffrey S. Huo, Amy E. DeZern(Johns Hopkins University), Christopher Gamper(Johns Hopkins University), Nancy Robey(Johns Hopkins Hospital), Kenneth R. Cooke(Sidney Kimmel Comprehensive Cancer Center), Nicolás J. Llosa(Sidney Kimmel Comprehensive Cancer Center), Diana Steppan(Johns Hopkins Hospital), Elias T. Zambidis(University of Maryland, Baltimore), Allen Chen(Johns Hopkins University), Mary Jo Holuba(Johns Hopkins Hospital)
Cited by 76
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
|Cancer Discovery|2014|1.5k
Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
|Biology of Blood and Marrow Transplantation|2009|595